All COVID-19 vaccines authorized in Canada are proven safe, effective and of high quality.
Name: Novavax Nuvaxovid® COVID-19 vaccine
Manufacturer: Novavax Inc.
Type: protein-based vaccine
Status: Approved by Health Canada
Approved for: Age 18 and older
How it’s given: Injection in muscle (usually the upper arm)
Number of doses: 2 doses
Who the vaccine is approved for
The vaccine is approved for people who are 18 years of age and older. Its safety and effectiveness in people younger than 18 years of age have not yet been established.
Effectiveness
Clinical trials showed that beginning 1 week after the second dose, Novavax Nuvaxovid® COVID-19 vaccine was:
- 90% effective in protecting trial participants aged 18 and above against COVID-19
Dosage
The dosing schedule approved by Health Canada is to give 2 doses 21 days apart, based on evidence from clinical trials. One dose contains 5 micrograms of the SARS-CoV-2 spike protein (original strain) with 50 micrograms of Matrix-M adjuvant.
Your province or territory decides when people receive their doses of the vaccine.
These decisions are based on public health recommendations and the latest evidence.